Navigation Links
Spherix Announces Termination of Arla License Agreement
Date:6/23/2009

ial to study the use of Naturlose as a treatment for Type 2 diabetes. Its Spherix Consulting subsidiary provides scientific and strategic support for suppliers, manufacturers, distributors and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products, and industrial chemicals and pesticides. For more information, please visit www.spherix.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of Naturlose, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our continuing efforts to develop Naturlose may be unsuccessful, our common stock could be delisted from the NASDAQ Capital Market, and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our current report on Form 8-K filed on October 10, 2007. Readers are cautioned n
'/>"/>

SOURCE Spherix Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Spherix Announces Full-Scale Production of Pharmaceutical Tagatose
2. Spherix Regains Full NASDAQ Compliance
3. Spherix to Exhibit at the BIO 2009 International Convention
4. Spherix Recruiting New Independent Director to Regain NASDAQ Compliance
5. Spherix Incorporated Announces the Death of A. Paul Cox, Jr., Chairman of the Board
6. Spherix Announces 2008 Financial Results
7. Spherix Reports 3rd Quarter Earnings
8. Spherix Transfers Stock Listing to Nasdaq Capital Market
9. Spherix Receives Nasdaq Letter Extending Minimum Bid Price Compliance Period
10. Spherix Receives NASDAQ Bid Price Deficiency Letter
11. Spherix Reports 1st Quarter Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... (PRWEB) October 27, 2014 Ryan Carfley ... this month to sit down with Bryan Hamilton, the publisher ... Solutions to discuss talent in the Research Triangle region of ... that were highlighted at the roundtable include the role ... the significance of work/life balance and the unique role that ...
(Date:10/27/2014)... 2014 The Italian company ... and sell its artificial "lower limb", after the ...      (Photo: http://photos.prnewswire.com/prnh/20141027/713097 ) ... the definitive judgement has arrived: Roadrunnerfoot, the small ... accessible hi-tech prostheses with composite materials, has won ...
(Date:10/27/2014)... 2014 Kalorama Information says that PCR is ... the United States and is ... researcher said the FDA,s Emergency Use Authorization (EUA) to authorize ... the detection of the Ebola virus was an indication ... assess the IVD industry and its biennial survey on ...
(Date:10/27/2014)... 27, 2014 New Q4-2014 incentives ... , an industry leading unified communication and collaboration ... agents to deliver cloud-based audio and web/video conferencing ... , With SoundConnect’s Q4 incentive partners ... and/or web conferencing licenses sold, now through December ...
Breaking Biology Technology:Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 3Italian Lower Limb Prosthesis Company Wins Lawsuit Against German Giant Ottobock 2Kalorama: PCR The Go-to Test in Ebola Fight 2Kalorama: PCR The Go-to Test in Ebola Fight 3SoundConnect Unveils Q4 Partner Incentives 2
... as an acceptable primary endpoint, for ... April 28 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: ... reached an agreement with the U.S. Food and Drug ... 3 registration trial of OGX-011, its lead product candidate ...
... containing microneedles has proven just as effective at ... immunization. A team of researchers at Emory University ... new microneedle skin patch method of delivering flu ... people because of decreased pain, increased convenience, lower ...
... of $264.5 million grows 7.8% year-over-year- Operating margin ... Net quarterly book-to-bill ratio equates to 1.25BOSTON, April ... PRXL ) today announced its financial results for ... three months ended March 31, 2009, PAREXEL,s consolidated ...
Cached Biology Technology:OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 2OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 3OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 4OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 5OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 6Flu vaccine given in microneedle skin patches proves effective in mice 2Flu vaccine given in microneedle skin patches proves effective in mice 3PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 2PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 3PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 4PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 5PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 6PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 7PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 8PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 9PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 10PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 11PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 12PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 13PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 14PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 15
(Date:10/29/2014)... in New York City on September 19, 2014, leading ... Society Professor of Genome Sciences and Medicine at the ... of Philosophy of Tel Aviv University, was awarded the ... In addition to her honorary degree from TAU, Prof. ... School of Medicine, and for the past 18 years ...
(Date:10/29/2014)... research potential of the Barcode of Life Data ... Biodiversity Data Journal (BDJ) used ... imported these into a human-readable text developed in manuscript ... were used to study the species distributions of ten ... , BOLD is originally designed to support the generation ...
(Date:10/29/2014)... Cancer Genomics of the Kidney consortium ( CAGEKID ... and exposure to aristolochic acid, an ingredient in ... Nature Communications , have important implications for public ... people every year, and in Central Europe incidence ... the International Cancer Genome Consortium (ICGC), has been ...
Breaking Biology News(10 mins):Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2Go straight and publish: From Barcode of Life Data Systems to scholarly publishing systems 2Kidney cancer in Central Europe 2
... Jewish Medical and Research Center report in the March ... proteins, known as fibulins 3 and 5, slow the ... vessels from sprouting. The proteins are promising candidates for ... fibulin proteins, which regulate cell proliferation, migration and invasion. ...
... A new UCLA imaging study shows that age-related breakdown ... wiring, correlates strongly with the presence of a key ... are detailed in the January edition of the peer-reviewed ... growing body of evidence that myelin breakdown is a ...
... in the home, but the presence of gas stresses out ... from the University of Nottingham have found that changes in ... warning of leaks in natural gas pipelines. "Our study ... monitor gas leaks via the spectrum of reflected light from ...
Cached Biology News:Proteins stop blood-vessel and tumor growth in mice 2Imaging study links key genetic risk for Alzheimer's disease to myelin breakdown 2Plants used to detect gas leaks, from outer space! 2